​

Capricor Therapeutics (CAPR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CAPR Stock Forecast

Capricor Therapeutics (CAPR) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $15.38, with a high of $21.50 and a low of $10.00. This represents a 7.78% increase from the last price of $14.27.

- $5 $10 $15 $20 $25 High: $21.5 Avg: $15.38 Low: $10 Last Closed Price: $14.27

CAPR Stock Rating

Capricor Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

CAPR Forecast vs Benchmarks

TypeNameUpside
StockCapricor Therapeutics7.78%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--6
Avg Price Target--$12.67
Last Closing Price$14.27$14.27$14.27
Upside/Downside---11.21%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2534---7
Dec, 2434---7
Nov, 2434---7
Oct, 2433---6
Sep, 2423---5
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024Edward TenthoffPiper Sandler$17.50$9.4385.58%22.63%
Oct 14, 2024Leland GershallOppenheimer$21.50$8.89141.84%50.67%
Sep 25, 2024Jason McCarthyMaxim Group$12.50$4.55174.73%-12.40%
Sep 25, 2024Joseph PantginisH.C. Wainwright$10.00$2.78259.71%-29.92%
Sep 17, 2024Leland GershallOppenheimer$7.50$2.54195.28%-47.44%
May 16, 2024Leland GershallOppenheimer$7.00$2.82148.23%-50.95%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Piper SandlerOverweightinitialise
Oct 14, 2024OppenheimerOutperformOutperformhold
Oct 11, 2024H.C. WainwrightBuyBuyhold
Sep 25, 2024Maxim GroupBuyBuyhold
Sep 24, 2024Cantor FitzgeraldOverweightOverweighthold
Sep 20, 2024OppenheimerBuyBuyhold
Sep 18, 2024H.C. WainwrightBuyBuyhold
Sep 17, 2024OppenheimerOutperformOutperformhold
Jul 02, 2024OppenheimerBuyBuyhold
Jul 02, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.87$-0.84$-1.18$-0.83-----
Avg Forecast$-0.88$-0.80$-1.22$-1.04$-1.19$-0.98$0.41$1.25$3.48
High Forecast$-1.06$-0.96$-2.51$-1.21$-1.35$-1.90$-1.20$-0.94$2.07
Low Forecast$-0.64$-0.58$-0.59$-0.87$-0.64$2.04$1.63$2.20$5.07
Surprise %-1.14%5.00%-3.28%-20.19%-----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$310.25K$244.90K$2.55M$25.18M-----
Avg Forecast$252.00K$222.50K$1.59M$21.05M$20.97M$44.47M$113.29M$184.74M$287.81M
High Forecast$198.26K$175.05K$960.35K$14.47M$20.66M$30.58M$113.29M$179.97M$197.92M
Low Forecast$291.47K$257.35K$2.89M$28.47M$21.45M$60.14M$113.29M$189.52M$389.25M
Surprise %23.12%10.07%59.84%19.62%-----

Net Income Forecast

$-100M $-50M $0 $50M $100M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-13.48M$-19.41M$-29.02M$-22.29M-----
Avg Forecast$-23.56M$-21.42M$-32.58M$-27.85M$-34.11M$-40.14M$18.31M$16.87M$93.10M
High Forecast$-28.36M$-25.79M$-67.10M$-32.39M$-36.08M$-50.88M$-32.13M$-25.17M$55.30M
Low Forecast$-17.03M$-15.48M$-15.73M$-23.31M$-17.12M$54.74M$43.65M$58.91M$135.75M
Surprise %-42.80%-9.40%-10.93%-19.97%-----

CAPR Forecast FAQ

Is Capricor Therapeutics stock a buy?

Capricor Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Capricor Therapeutics is a favorable investment for most analysts.

What is Capricor Therapeutics's price target?

Capricor Therapeutics's price target, set by 6 Wall Street analysts, averages $15.38 over the next 12 months. The price target range spans from $10 at the low end to $21.5 at the high end, suggesting a potential 7.78% change from the previous close price of $14.27.

How does Capricor Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Capricor Therapeutics stock forecast shows a 7.78% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Capricor Therapeutics over the past three months?

  • January 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Capricor Therapeutics’s EPS forecast?

Capricor Therapeutics's average annual EPS forecast for its fiscal year ending in December is -1.19 for 2024, a 43.37% increase from the reported $-0.83 in 2023. The prediction for 2025 is $-0.98, $0.41 for 2026, $1.25 for 2027, and $3.48 for 2028.

What is Capricor Therapeutics’s revenue forecast?

Capricor Therapeutics's average annual revenue forecast for its fiscal year ending in December is $20.97M for 2024, a -16.72% decrease from the reported $25.18M in 2023. The forecast for 2025 is $44.47M, $113.29M for 2026, $184.74M for 2027, and $287.81M for 2028.

What is Capricor Therapeutics’s net income forecast?

For its fiscal year ending in December, Capricor Therapeutics's average annual net income forecast is $-34.113M for 2024, reflecting an 53.06% increase from the reported $-22.288M in 2023. The projection for 2025 is $-40.142M, $18.31M for 2026, $16.87M for 2027, and $93.1M for 2028.